IRIDEX Corporation (Nasdaq: IRIX) today announced approval and commercial availability in Japan for its extended family of EndoProbe laser delivery devices. The EndoProbe is an intraocular laser delivery device used during vitreoretinal surgery for the treatment of multiple disorders including: diabetic retinopathy, retinal detachments and vitreous hemorrhage. IRIDEX distributes products in Japan through their partner, TOMEY Corporation.
"This approval represents another step in our global strategy of growing our disposable instrumentation product revenues," said Theodore A. Boutacoff, President and Chief Executive Officer of IRIDEX. "TOMEY has been an outstanding partner in selling our ophthalmic laser systems and delivery devices into the Japanese market. We are looking forward to the ramp-up and sales of these delivery devices."
The probes being introduced may be used with the current installed base of IRIDEX laser systems in Japan. "The EndoProbe product family includes single-use laser delivery devices with standard, shaped and specialized designs to complement each surgeon's personal technique," commented Eduardo Arias, SVP of International Sales and Business Development. "We expect sales of this expanded lineup of EndoProbe consumables in Japan will show positive incremental increases in the near future."
Bariatric surgery outperforms traditional treatments for long-term diabetes control